Symbiomix is a held biopharmaceutical company with a focus on women's health. The company's lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment in the United States for bacterial vaginosis (BV), a common but underappreciated gynecological infection that greatly increases the risk of serious health problems.

Symbiomix is a held biopharmaceutical company with a focus on women's health. The company's lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment in the United States for bacterial vaginosis (BV),...Show all